DNA vaccination strategies for anti-tumour effective gene therapy protocols

Cancer Immunology, Immunotherapy

Volumn 59, Issue 10, 2010, Pages 1583-1591

  Signori, Emanuela ^a,b   Iurescia, Sandra ^a   Massi, Emanuela ^a,b   Fioretti, Daniela ^a   Chiarella, Pieranna ^a,b   De Robertis, Mariangela ^a,b   Rinaldi, Monica ^a   Tonon, Giancarlo ^c   Fazio, Vito Michele ^b  

^a CNR   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c POLARIS   (Italy)

Author keywords

B cell lymphoma; Cancer vaccine; DNA vaccination; Genetic immunisation

Indexed keywords

CANCER VACCINE; DNA VACCINE; EPITOPE; IMMUNOGLOBULIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TETANUS TOXIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; B CELL LYMPHOMA; BINDING AFFINITY; CANCER GENE THERAPY; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL PROTOCOL; DNA IMMUNIZATION; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; ELECTROPORATION; ENDOPLASMIC RETICULUM; GENETIC IMMUNIZATION; HAPLOTYPE; HELPER CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; LYMPHOCYTE ACTIVATION; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROMOTER REGION; REVIEW; SURVIVAL RATE;

ANIMALS; CANCER VACCINES; DISEASE MODELS, ANIMAL; GENE THERAPY; HUMANS; LYMPHOMA; MICE; VACCINES, DNA;

EID: 77955553809     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0853-x     Document Type: Review

References (50)

1. K Baraldo E Mori A Bartoloni, et al. 2004 N19 polyepitope as a carrier for enhanced immunogenicity and protective efficacy of meningococcal conjugate vaccines Infect Immun 72 4884 4887 10.1128/IAI.72.8.4884-4887.2004 1:CAS:528:DC%2BD2cXmtlymtrg%3D 15271954 (Pubitemid 38989352)
2. CN Baxevanis SA Perez M Papamichail 2009 Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy Cancer Immunol Immunother 58 317 324 10.1007/s00262-008-0576-4 18704409
3. F Benvenuti M Cesco-Gaspere OR Burrone 2002 Anti-idiotypic DNA vaccines for B-cell lymphoma therapy Front Biosci 7 228 234 10.2741/benvenut
4. AM Bodles-Brakhop R Draghia-Akli 2008 DNA vaccination and gene therapy: optimization and delivery for cancer therapy Expert Rev Vaccines 7 1085 1101 10.1586/14760584.7.7.1085 1:CAS:528:DC%2BD1cXhtVOiur%2FL 18767956
5. S Buchan E Grønevik I Mathiesen CA King FK Stevenson J Rice 2005 Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen J Immunol 174 6292 6298 1:CAS:528:DC%2BD2MXjvV2mtbo%3D 15879128
6. MJ Campbell W Carroll S Kon, et al. 1987 Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits J Immunol 139 2825 2833 1:CAS:528:DyaL1cXitVaguw%3D%3D 3498771
7. MJ Campbell L Esserman R Levy 1988 Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide J Immunol 141 3227 3233 1:CAS:528:DyaL1cXmt1ajt7s%3D 3049819
8. MA Cheever JP Allison AS Ferris, et al. 2009 The prioritization of cancer antigen: a national cancer institute pilot project for the acceleration of translational research Clin Cancer Res 15 5323 5337 10.1158/1078-0432.CCR-09- 0737 19723653
9. P Chiarella E Massi M De Robertis VM Fazio E Signori 2008 Strategies for effective naked-DNA vaccination against infectious diseases Recent Pat Antiinfect Drug Discov 3 93 101 10.2174/157489108784746623 1:CAS:528: DC%2BD1cXos1Kjs7o%3D 18673122
10. P Chiarella E Massi M De Robertis VM Fazio E Signori 2009 Recent Advances in Epitope Design for Immunotherapy of Cancer Recent Pat Anticancer Drug Discov 4 227 240 10.2174/157489209789206922 1:CAS:528:DC%2BD1MXht12qt7fF 19522699
11. P Chiarella E Massi M De Robertis A Sibilio P Parrella VM Fazio 2008 Electroporation of skeletal muscle induces danger signal release and antigen-presenting cell recruitment independently of DNA vaccine administration Expert Opin Biol Ther 8 1645 1657 10.1517/14712598.8.11.1645 1:CAS:528:DC%2BD1cXht1artrbP 18847301
12. P Chiarella E Massi M De Robertis E Signori VM Fazio 2007 Adjuvants in vaccines and for immunisation: current trends Expert Opin Biol Ther 7 1551 1562 10.1517/14712598.7.10.1551 1:CAS:528:DC%2BD2sXhtFejsrvE 17916047 (Pubitemid 47597143)
13. H Davtyan M Mkrtichyan N Movsesyan, et al. 2010 DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice Gene Ther 17 261 271 10.1038/gt.2009.140 1:CAS:528: DC%2BD1MXhtlaksrrF 19865176
14. S Demotz C Barbey G Corradin A Amoroso A Lanzavecchia 1993 The set of naturally processed peptides displayed by DR molecules is tuned by polymorphism of residue 86 Eur J Immunol 23 425 432 10.1002/eji.1830230219 1:CAS:528:DyaK3sXhsVGmsr0%3D 7679644
15. Fioretti D, Iurescia S, Fazio VM, Rinaldi M (2010) DNA vaccines: developing new strategies against cancer. J Biomed Biotech (in press)
16. CL Fong CL Mok KM Hui 2006 Intramuscular immunization with plasmid coexpressing tumour antigen and Flt-3L results in potent tumour regression Gene Ther 13 245 256 10.1038/sj.gt.3302639 1:CAS:528:DC%2BD28Xmtlymug%3D%3D 16163376 (Pubitemid 43148647)
17. AB Fredriksen I Sandlie B Bogen 2006 DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells Mol Ther 13 776 785 10.1016/j.ymthe.2005.10.019 1:CAS:528:DC%2BD28XjtFOktbw%3D 16414309
18. JA Gollob JW Mier K Veenstra 2000 Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-γ induction is associated with clinical response Clin Cancer Res 6 1678 1694 1:CAS:528:DC%2BD3cXktVWisrs%3D 10815886
19. M Grujic PJ Holst JP Christensen AR Thomsen 2009 Fusion of a viral antigen to invariant chain leads to augmented T-cell immunity and improved protection in gene-gun DNA-vaccinated mice J Gen Virol 90 414 422 10.1099/vir.0.002105-0 1:CAS:528:DC%2BD1MXhslejt7c%3D 19141451
20. L Hansson H Rabbani J Fagerberg A Osterborg H Mellstedt 2003 T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma Blood 101 4930 4936 10.1182/blood-2002-04-1250 1:CAS:528:DC%2BD3sXkslCjsLY%3D 12576325
21. PC Ho DA Mutch KD Winkel, et al. 1990 Identification of two promiscuous T cell epitopes from tetanus toxin Eur J Immunol 20 477 483 10.1002/eji. 1830200304 1:CAS:528:DyaK3cXksFKqt7w%3D 1690656
22. SA Hurvitz JM Timmerman 2005 Current status of therapeutic vaccines for non-Hodgkin's lymphoma Curr Opin Oncol 17 432 440 10.1097/01.cco.0000174040. 52427.83 1:CAS:528:DC%2BD2MXnt1Shtbs%3D 16093791 (Pubitemid 41224922)
23. Iurescia S, Fioretti D, Pierimarchi P et al (2010) Genetic Immunization with CDR3-Based Fusion Vaccine Confers Protection and Long Term Tumor-Free Survival in a Mouse Model of Lymphoma. J Biomed Biotech (in press)
24. KL Knutson ML Disis 2005 Tumor antigen-specific T helper cells in cancer immunity and immunotherapy Cancer Immunol Immunother 54 721 728 10.1007/s00262-004-0653-2 1:CAS:528:DC%2BD2MXmtVajt78%3D 16010587 (Pubitemid 40977140)
25. MA Kutzler DB Weiner 2008 DNA vaccines: ready for prime time? Nat Rev Genet 9 776 788 10.1038/nrg2432 1:CAS:528:DC%2BD1cXhtFeitrvL 18781156
26. LW Kwak MJ Campbell DK Czerwinski S Hart RA Miller R Levy 1992 Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors N Engl J Med 327 1209 1215 1:STN:280:DyaK3s%2FisVOjtQ%3D%3D 1406793
27. M Kwissa SP Kasturi B Pulendran 2007 The Science of adjuvants Expert Rev Vaccines 6 673 684 10.1586/14760584.6.5.673 1:CAS:528:DC%2BD2sXhtFGgsrrN 17931149 (Pubitemid 47607845)
28. A Liso R Benedetti M Fagioli A Mariano B Falini 2005 Modulatory effects of mycobacterial heat-shock protein 70 in DNA vaccination against lymphoma Haematologica 90 60 65 1:CAS:528:DC%2BD2MXhvFGjsLk%3D 15642670
29. B Livingston C Crimi M Newman, et al. 2002 A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes J Immunol 168 5499 5506 1:CAS:528:DC%2BD38XktFCrs7k%3D 12023344
30. BD Livingston M Newman C Crimi D McKinney R Chesnut A Sette 2001 Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines Vaccine 19 4652 4660 10.1016/S0264-410X(01)00233-X 1:CAS:528: DC%2BD3MXmsFWrt78%3D 11535313 (Pubitemid 32800747)
31. Y Lu K Ouyang J Fang, et al. 2009 Improved efficacy of DNA vaccination against prostate carcinoma by boosting with recombinant protein vaccine and by introduction of a novel adjuvant epitope Vaccine 27 5411 5418 10.1016/j.vaccine.2009.06.089 1:CAS:528:DC%2BD1MXpvF2rtr8%3D 19616501
32. D Luo WM Saltzman 2000 Synthetic DNA delivery systems Nat Biotechnol 18 33 37 10.1038/71889 1:CAS:528:DC%2BD3cXjs12jsQ%3D%3D 10625387 (Review) (Pubitemid 30041168)
33. DH Lynch A Andreasen E Maraskovsky J Whitmore RE Miller JC Schuh 1997 Flt3 ligand induces tumor regression and antitumor immune responses in vivo Nat Med 3 625 631 10.1038/nm0697-625 1:CAS:528:DyaK2sXjsFOisbc%3D 9176488 (Pubitemid 27264971)
34. DL Montgomery JJ Donnelly JW Shiver MA Liu JB Ulmer 1994 Protein expression in vivo by injection of polynucleotides Curr Opin Biotechnol 5 505 510 10.1016/0958-1669(94)90065-5 1:CAS:528:DyaK2cXmvFymtLw%3D 7765464 (Pubitemid 24321418)
35. DT O'Hagan NM Valiante 2003 Recent advances in the discovery and delivery of vaccine adjuvants Nat Rev Drug Discov 2 727 735 10.1038/nrd1176 12951579 (Review)
36. CA Pacak Y Sakai BD Thattaliyath CS Mah BJ Byrne 2008 Tissue specific promoters improve specificity of AAV9 mediated transgene expression following intra-vascular gene delivery in neonatal mice Genet Vaccines Ther 6 13 10.1186/1479-0556-6-13 18811960
37. P Panina-Bordignon A Tan A Termijtelen S Demotz G Corradin A Lanzavecchia 1989 Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells Eur J Immunol 19 2237 2242 10.1002/eji.1830191209 1:CAS:528:DyaK3cXhvFKhu78%3D 2481588 (Pubitemid 20024747)
38. MA Perales J Yuan S Powel, et al. 2008 Phase I/II study of GMCSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma Mol Ther 16 2022 2029 10.1038/mt.2008.196 1:CAS:528:DC%2BD1cXhsVSjsbnK 18797450
39. J Rice S Buchan FK Stevenson 2002 Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen J Immunol 169 3908 3913 1:CAS:528:DC%2BD38XnsFeltbw%3D 12244189
40. J Rice T Elliott S Buchan FK Stevenson 2001 DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: implications for cancer vaccines J Immunol 167 1558 1565 1:CAS:528: DC%2BD3MXls1Wrs7s%3D 11466377
41. J Rice CH Ottensmeier FK Stevenson 2008 DNA vaccines: precision tools for activating effective immunity against cancer Nat Rev Cancer 8 108 120 10.1038/nrc2326 1:CAS:528:DC%2BD1cXhtVGiu7w%3D 18219306 (Pubitemid 351161331)
42. M Rinaldi D Fioretti S Iurescia E Signori, et al. 2008 Anti-tumor immunity induced by CDR3-based DNA vaccination in a murine B-cell lymphoma model Biochem Biophys Res Commun 370 279 284 10.1016/j.bbrc.2008.03.076 1:CAS:528:DC%2BD1cXlslCqtrY%3D 18364239
43. M Rinaldi F Ria P Parrella E Signori, et al. 2001 Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B lymphoproliferative disorders specifically react with patients' tumor cells Cancer Res 61 1555 1562 1:CAS:528:DC%2BD3MXhvVeltbs%3D 11245465
44. A Sette M Newman B Livingston, et al. 2002 Optimizing vaccine design for cellular processing, MHC binding and TCR recognition Tissue Antigens 59 443 451 10.1034/j.1399-0039.2002.590601.x 1:CAS:528:DC%2BD38XnvVynt74%3D 12445314 Review (Pubitemid 35034464)
45. FK Stevenson J Rice CH Ottensmeier SM Thirdborough D Zhu 2004 DNA fusion gene vaccines against cancer: from the laboratory to the clinic Immunol Rev 199 156 180 10.1111/j.0105-2896.2004.00145.x 1:CAS:528:DC%2BD2cXltFygsLs%3D 15233733 (Pubitemid 38736770)
46. SM Sumida PF McKay DM Truitt, et al. 2004 Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines J Clin Invest 114 1334 1342 1:CAS:528:DC%2BD2cXpsFCgtrc%3D 15520866
47. MP Velders S Weijzen GL Eiben, et al. 2001 Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine J Immunol 166 5366 5373 1:CAS:528: DC%2BD3MXjtFyrt7c%3D 11313372
48. QM Wang SH Sun ZL Hu, et al. 2004 Epitope DNA vaccines against tuberculosis: spacers and ubiquitin modulates cellular immune responses elicited by epitope DNA vaccine Scand J Immunol 60 219 225 10.1111/j.0300-9475.2004. 01442.x 1:CAS:528:DC%2BD2cXnvFWmtb0%3D 15320877 (Pubitemid 39141251)
49. W Xu Y Chu R Zhang H Xu Y Wang S Xiong 2005 Endoplasmic reticulum targeting sequence enhances HBV-specific cytotoxic T lymphocytes induced by a CTL epitope-based DNA vaccine Virology 334 255 263 10.1016/j.virol.2005.01.040 1:CAS:528:DC%2BD2MXisVCltbo%3D 15780875 (Pubitemid 40386959)
50. G Zeng 2001 MHC class II-restricted tumor antigens recognized by CD4+ T cells: new strategies for cancer vaccine design J Immunother 24 195 204 10.1097/00002371-200105000-00002 1:CAS:528:DC%2BD3MXksVyhsr0%3D (Pubitemid 32479709)